Operational efficiency remains elusive, with the company reporting a negative free cash flow margin of -8.7% in 2026Q1 despite aggressive capital deployment.
| Cash from Operations | -45.93M | -23.51M | -3.07M | -449.49K | -140.38K | 121.44K |
| Operating CF Margin % | - | -1290.91% | -113.02% | -11.93% | -3.71% | 4.85% |
| Operating CF Growth % | -4600.14% | -664.88% | -583.86% | -220.19% | -215.6% | - |
| Net Income | -289.97M | -52.23M | -3.62M | -1.62M | -2.54M | 149.34K |
| Depreciation & Amortization | 1.34M | 241.99K | 220.33K | 203.22K | 122K | 63.4K |
| Stock-Based Compensation | 3.96M | 2.36M | 240.91K | 414.69K | 2.22M | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 249.6M | 30.17M | 384.48K | 433.7K | 28.63K | 1 |
| Working Capital Changes | -10.86M | -4.05M | -301.97K | 116.36K | 33.23K | -91.29K |
| Change in Receivables | 11.38K | 0 | -40.96K | -15.88K | -7.12K | 401 |
| Change in Inventory | 1.59K | 0 | 58.9K | -13.63K | 10.2K | -30.64K |
| Change in Payables | -8.24M | -1.95M | -6.08K | 163.55K | 122.31K | 0 |
| Cash from Investing | -643.29M | -680.02M | -401.63K | -14.42K | -317.39K | -63.6K |
| Capital Expenditures | -61.38K | -234.38K | -13.29K | -14.42K | -317.39K | -63.6K |
| CapEx % of Revenue | 1.57% | 12.87% | 0.49% | 0.38% | 8.38% | 2.54% |
| Acquisitions | 23.73M | -29.82M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | -684.37M | -655.02M | -388.34K | 0 | 0 | 0 |
| Cash from Financing | 723.38M | 723.85M | 5.22M | 802.49K | 550K | -45.34K |
| Debt Issued (Net) | 191.29M | 191.21M | -614.86K | 802.49K | 150K | -47.34K |
| Equity Issued (Net) | 522.87M | 523.42M | 5.84M | 0 | 400K | 2K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -871.4K | -320.4K | -22.14K | 0 | 0 | 0 |
| Other Financing | 9.22M | 9.22M | 0 | 0 | 0 | 0 |
| Net Change in Cash | 34.16M | 20.31M | 1.75M | 338.58K | 92.23K | 94.69K |
| Free Cash Flow | -45.99M | -23.75M | -3.48M | -463.91K | -457.77K | 57.84K |
| FCF Margin % | -1173.39% | -1303.78% | -127.78% | -12.31% | -12.09% | 2.31% |
| FCF Growth % | -1079.14% | -583.23% | -649.18% | -1.34% | -891.44% | - |
| FCF per Share | -2.89 | -2.09 | -0.64 | -0.08 | -0.08 | 0.01 |
| FCF Conversion (FCF/Net Income) | 0.16x | 0.45x | 0.85x | 0.28x | 0.06x | 0.81x |
| Interest Paid | 0 | 0 | 19.23K | 34.62K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Unsustainable cash burn rate
As reported in recent financial statements, Nakamoto Inc. exhibits a persistent divergence between net income and operating cash flow, with the OCF/NI ratio fluctuating wildly and failing to provide a consistent signal of earnings quality amidst deep, recurring quarterly losses.
The extreme volatility in the relationship between net income and operating cash flow suggests that accounting accruals are not effectively capturing the underlying cash reality of the business. Investors should monitor this disconnect, as it implies that the company's reported losses may not fully reflect the actual cash-based operational burn occurring within its clinical service segments.
Based on the company's reported figures, the free cash flow margin has remained consistently negative, reaching a low of -179.0% in 2025Q1, which underscores the structural inability of the current clinical model to generate self-sustaining cash flow despite the company's attempts at operational scaling.
The persistent negative FCF trajectory indicates that the company is consuming its cash reserves at an accelerating pace relative to its revenue base. This trend warrants further investigation into whether the current cash position is being utilized for genuine growth initiatives or simply to fund the ongoing operational deficits of its Utah-based clinical facilities.
According to recent SEC filings, Nakamoto Inc. has experienced erratic working capital changes, including a significant $6.7 million outflow in 2026Q1, which suggests that the company is struggling to manage its cash conversion cycle effectively while navigating a period of sharp revenue contraction.
The inconsistency in working capital movements appears to reflect poor control over accounts receivable and payables management. Such instability may indicate that the company is facing difficulty in collecting payments from its clinical patient base or is being forced to accelerate vendor payments to maintain its service infrastructure.
As indicated by the provided data, Nakamoto Inc. has engaged in sporadic share repurchases and acquisitions, such as the $8.7 million acquisition in 2026Q1, despite the company's core clinical operations failing to demonstrate a path toward positive cash flow generation.
The decision to deploy capital toward acquisitions while the core business is burning cash suggests a potential misalignment between management's capital allocation strategy and the company's immediate liquidity needs. Investors should monitor whether these acquisitions are intended to provide a necessary pivot or if they represent a distraction from the urgent requirement to stabilize the primary clinical model.
Quick answers to the most common questions about buying NAKA stock.
Nakamoto Inc. (NAKA) generated $-23.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Nakamoto Inc. (NAKA) reported negative free cash flow of $23.7M in 2025, indicating capital requirements exceeded cash from operations.
Nakamoto Inc. (NAKA) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Nakamoto Inc. (NAKA) spent $0.3M on share repurchases. This shows the company's commitment to returning capital to its equity investors.